The Use Of GDP (Gemcitabine, Dexamethasone and Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas

被引：1
|
作者：
Lavoie, Jean-Michel
Connors, Joseph M.
Villa, Diego
Klasa, Richard
Shenkier, Tamara
Gascoyne, Randy D.
Gerrie, Alina S.
Sehn, Laurie H.
Savage, Kerry J.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1804.1804
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1804
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial
    Park, Byeong-Bae
    Kim, Won Seog
    Suh, Cheolwon
    Shin, Dong-Yeop
    Kim, Jeong-A
    Kim, Hoon-Gu
    Lee, Won Sik
    ANNALS OF HEMATOLOGY, 2015, 94 (11) : 1845 - 1851
  • [2] Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial
    Byeong-Bae Park
    Won Seog Kim
    Cheolwon Suh
    Dong-Yeop Shin
    Jeong-A Kim
    Hoon-Gu Kim
    Won Sik Lee
    Annals of Hematology, 2015, 94 : 1845 - 1851
  • [3] Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas
    Jia, Bo
    Hu, Shaoxuan
    Yang, Jianliang
    Zhou, Shengyu
    Liu, Peng
    Qin, Yan
    Gui, Lin
    Yang, Sheng
    Lin, Hua
    Zhang, Changgong
    Xing, Puyuan
    Wang, Lin
    Dong, Mei
    Zhou, Liqiang
    Sun, Yan
    He, Xiaohui
    Shi, Yuankai
    HEMATOLOGY, 2016, 21 (09) : 536 - 541
  • [4] Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma—not otherwise specified
    Fei Qi
    Mei Dong
    Xiaohui He
    Yexiong Li
    Weihu Wang
    Peng Liu
    Jianliang Yang
    Lin Gui
    Changgong Zhang
    Sheng Yang
    Shengyu Zhou
    Yuankai Shi
    Annals of Hematology, 2017, 96 : 245 - 251
  • [5] COPANLISIB PLUS GEMCITABINE HAS EFFICACY IN PERIPHERAL T-CELL LYMPHOMAS
    Yhim, H. Y.
    Kim, T.
    Kim, S. J.
    Shin, H. J.
    Koh, Y.
    Kim, J. S.
    CANCER DISCOVERY, 2021, 11 (05) : 1007 - 1007
  • [6] Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma
    Kato, Harumi
    Yamamoto, Kazuhito
    Higuchi, Yusuke
    Yamamoto, Hideyuki
    Saito, Toko
    Taji, Hirofumi
    Yatabe, Yasushi
    Nakamura, Shigeo
    Kinoshita, Tomohiro
    CHEMOTHERAPY, 2017, 62 (01) : 19 - 22
  • [7] Peripheral T-cell lymphomas. Primary and relapsetreatment
    Wulf, G.
    Weber, T.
    ONKOLOGE, 2019, 25 (10): : 892 - 898
  • [8] Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified
    Qi, Fei
    Dong, Mei
    He, Xiaohui
    Li, Yexiong
    Wang, Weihu
    Liu, Peng
    Yang, Jianliang
    Gui, Lin
    Zhang, Changgong
    Yang, Sheng
    Zhou, Shengyu
    Shi, Yuankai
    ANNALS OF HEMATOLOGY, 2017, 96 (02) : 245 - 251
  • [9] Targeted molecular therapy in peripheral T-cell lymphomas
    Roncolato, Fernando
    Gazzola, Anna
    Zinzani, Pier Luigi
    Pileri, Stefano A.
    Piccaluga, Pier Paolo
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (05) : 551 - 562
  • [10] PERIPHERAL T-CELL LYMPHOMAS
    STEIN, H
    DIENEMANN, D
    DALLENBACH, F
    KRUSCHWITZ, M
    ANNALS OF ONCOLOGY, 1991, 2 : 163 - 169
12345